

Frank Litvack M.D. is a native of Montreal, Canada. He received his undergraduate and medical education at McGill University. He received his MD in 1979 at the age of twenty-three. Dr. Litvack completed his residency in Internal Medicine at McGill. In 1982 he moved to Los Angeles to begin his three-year Cardiovascular Fellowship at Cedars-Sinai. From 1986 until 2000 he was Co-Director at the Cardiovascular Intervention Center at Cedars-Sinai Medical Center in Los Angeles where he built and directed a widely renowned clinical and research program in Interventional Cardiology. Dr. Litvack was an active clinician, teacher and a practitioner of 'bench-to-bedside' research. This productive period led to a number of innovations in Interventional Cardiology.

Dr. Litvack attained the rank of Professor of Medicine at the UCLA School of Medicine and was board certified in three specialties- Internal Medicine, Cardiovascular Diseases and Interventional Cardiology. During his academic medical career he published extensively in various areas of research related to Interventional Cardiology. Dr. Litvack is the author of more than one hundred research articles and chapters. His primary focus was translational research involving novel therapies for patients with coronary artery and valvular heart disease. Dr. Litvack is the recipient of the Society of Photo-optical and Instrument Engineers (SPIE) Leon Goldman Award for Medical Excellence. He is an inductee in the United States Space Foundation Hall of Fame for "The Unique Secondary Use of NASA Technology" for his work translating Excimer laser technology from the Jet Propulsion Laboratories into the clinic. Dr. Litvack is a Fellow of the American College of Cardiology. During his academic career, he was Principal Investigator on a 5 year NIH Young Investigator Award and Co-Investigator on both NIH SCOR and RO1 grants.

Dr. Litvack has been an entrepreneur and executive in the medical technology industry having been involved in several start-up medical companies. These include;

1. Co- Founder and outside Director of Advanced Interventional Systems in 1985.
2. Co- Founder and Chairman of Progressive Angioplasty Systems Inc., the developer of the balloon delivery system for the U.S. launch of the

- Johnson & Johnson *Palmaz Schatz* stent and other medical products. This company was sold to United States Surgical Corporation in 1998.
3. Chairman of Savacor Inc., a developer of implantable monitors for the treatment of Congestive Heart Failure. Savacor was sold to St. Jude Medical in 2005.
 4. Chairman & CEO of Conor MedSystems Inc. from 2002-2007. This company was a developer of drug delivery stents. Dr Litvack led efforts that raised approximately \$80 million privately and close to \$100 million in two public offerings. In 2002 the company was valued at \$12 million. It was sold to Johnson and Johnson in 2007.
 5. Co-Founder and Chairman of iTherX pharmaceuticals. This venture-backed company is currently engaged in two, Phase 1b clinical trials with its novel viral entry-blocking molecule for Hepatitis C.
 6. Co-Founder of Reprise Medical Technologies, a Medical Device Incubator located in Menlo Park.
 7. Co-Founder and Chairman of Entourage Medical Technologies a venture backed developer of novel devices for the treatment of Structural Heart Disease.

Dr. Litvack serves on Boards of several life science companies including Entourage Medical (Structural Heart), Recor Medical (Structural Heart), Nile Therapeutics Inc (Specialty Pharmaceutical), One Lambda Inc (Molecular Diagnostics), Pervasis Therapeutics (Cell Therapy) and iTherx Pharmaceuticals (Biotechnology). He has been an Advisor to Capricor Inc., a cardiac stem cell company. Dr. Litvack serves on the Health Advisory Board of RAND Corporation.